Abstract:In the realm of enzymology, Carbonic anhydrase (CA) emerges as a pivotal protagonist orchestrating the rapid conversion of carbon dioxide and water into bicarbonate ions and hydrogen ions, respectively. Carbonic anhydrase inhibitors (CAIs) are the class of drugs that target various isoforms of the enzyme, and these inhibitors play a crucial role in the treatment and management of multiple diseases such as cancer, glaucoma, high altitude sickness, rheumatoid arthritis, obesity, epilepsy, and sleep apnea. Several structural classes of CAIs developed till date possess unique architects of the pharmacophoric requirements around the central core moiety for the selective targeting of various isoforms of the CA. Recent advancements in drug design and development, along with technologies that aid in structure determination, have led to the development of several isoform-selective inhibitors of CA enzymes. However, their therapeutic utility has still not been fulfilled due to the lack of desired potency, isoform selectivity, and pharmacokinetic properties. This review covers the most recent approaches used by different researchers, which are concerned with the development of isoform-selective carbonic anhydrase inhibitors belonging to distinct structural classes like sulphonamides, carbazoles, selenols, coumarin, organotelluride, topiramate, thiophene, triazole, uracil-modified benzylic amines, and thiourea etc. In addition, their structure–activity relationships, biological evaluation, and in silico studies as well as the forthcoming avenues of advancements have been discussed. This review serves as a valuable resource for developing potent and efficacious CAIs with remarkable therapeutic implications, offering insights into their potency, specificity, and potential clinical applications.

Advances in the structural annotation of human carbonic anhydrases and impact on future drug discovery

Advances in structure-based drug discovery of carbonic anhydrase inhibitors

Exploiting the hydrophobic and hydrophilic binding sites for designing carbonic anhydrase inhibitors

Progress in the development of human carbonic anhydrase inhibitors and their pharmacological applications: Where are we today?

Designing of novel carbonic anhydrase inhibitors and activators

Recent advances in the discovery of zinc-binding motifs for the development of carbonic anhydrase inhibitors

Carbonic anhydrase inhibition/activation: trip of a scientist around the world in the search of novel chemotypes and drug targets

Carbonic anhydrase inhibitors and their therapeutic potential

Carbonic anhydrase inhibitors and their potential in a range of therapeutic areas

Carbonic anhydrase inhibitors

Carbonic anhydrases: Moiety appended derivatives, medicinal and pharmacological implications

Carbonic anhydrase inhibitors and activators for novel therapeutic applications

Discovering Isozyme‐Selective Inhibitor Scaffolds of Human Carbonic Anhydrases Using Structural Alignment and De Novo Drug Design Approaches

Dual-Tail Approach to Discovery of Novel Carbonic Anhydrase Ix Inhibitors by Simultaneously Matching the Hydrophobic and Hydrophilic Halves of the Active Site

Structure and function of carbonic anhydrases

Carbonic anhydrases: novel therapeutic applications for inhibitors and activators

Structure-based drug discovery of carbonic anhydrase inhibitors

Emerging role of carbonic anhydrase inhibitors

Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery

Carbonic anhydrases as targets for medicinal chemistry

(In) organic anions as carbonic anhydrase inhibitors